Anal Cancer Screening Cost-Effective for HIV+ Men Who Have Sex With Men ≥35 Years of Age
By Elana Gotkine HealthDay Reporter
TUESDAY, June 17, 2025 -- For men who have sex with men (MSM) with HIV, aged 35 years or older, anal cancer screening is cost-effective, according to a study published online June 17 in the Annals of Internal Medicine.
Ashish A. Deshmukh, Ph.D., M.P.H., from the Medical University of South Carolina in Charleston, and colleagues quantified the cost-effectiveness and benefits versus harms of different anal cancer screening strategies in a microsimulation model for MSM with HIV.
The researchers found that in the base-case analysis, screening initiation at age 35 years or older using cytology dominated initiation at ages 40 and 45 years or older, with incremental cost-effectiveness ratios (ICERs) varying from $87,731 to $350,100 for a quadrennial versus annual interval. In the comparative analysis, quadrennial human papillomavirus (HPV)16, quadrennial HPV16/18, triennial HPV16/18, triennial high-risk HPV (hrHPV), biennial HPV16/18, biennial hrHPV, annual cytology with hrHPV triage, and annual hrHPV were on the frontier of cost-effectiveness, with ICERs varying from $81,341 to $2,510,847. Triage options offered the most efficient high-resolution anoscopy use in the harm-to-benefit analysis. In the sensitivity analysis, for newly eligible persons, ICERs decreased. ICERs for cytology varied from $70,750 (quadrennial) to $223,895 (annual) for 35-year-old newly eligible MSM with HIV.
"These findings imply that value-based prioritization of anal cancer screening is needed to optimize screening use," the authors write. "The findings of this study could inform screening guidelines, improve practices, reduce screening harms and enhance benefits, and optimally streamline the use of scarce screening resources."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
2,770 Cases of Arboviral Disease Reported in 48 States and D.C. in 2023
TUESDAY, June 17, 2025 -- In 2023, 48 states and the District of Columbia reported 2,770 human arboviral disease cases, with West Nile Virus (WNV) being the most common, according...
New Model Developed for Identifying DVT in Epithelial Ovarian Cancer
TUESDAY, June 17, 2025 -- A model with eight independent risk factors can predict the risk for deep vein thrombosis (DVT) in patients with epithelial ovarian cancer (EOC)...
Electronic Nudge Letters Do Not Improve Guideline-Directed Medical Therapy in CKD
TUESDAY, June 17, 2025 -- Neither delivery of electronic nudge letters nor letters to general practice increase uptake of guideline-directed medical therapy (GDMT) among patients...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.